What impact do you think this claim will have on the value of Libigel?
32. The method according to claim 28, wherein the decrease in the risk of a cardiovascular event in the treated women compared to the risk of cardiovascular events in untreated women is at least 70%.
If the February 14 conference trumps both a Bio-t-gel PDUFA approval and a statement in relation this patent application. Expect very big movement on the share price.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.